2 completed, 1 active not recruiting, 1 not yet recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
Follow Lip Neoplasms: new trials by email Literature Review of Lip Neoplasms trials Research Report on Lip Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-11-30 | 2026-11-03 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma Durvalumab, Carboplatin, Nab-paclitaxel - Carcinoma, Squamous Cell, Oral Cancer | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 39 | 2017-12-19 | 2026-02-23 |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma Cetuximab, Ficlatuzumab - Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | University of Arizona | 78 | 2017-12-05 | 2024-09-04 |
Mouth Neoplasms (4) · Carcinoma, Squamous Cell (3) · Head and Neck Neoplasms (3) · Laryngeal Neoplasms (3) · Oropharyngeal Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Tongue Neoplasms (2) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Mucoepidermoid (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1)
Carcinoma (4) · Lip Diseases (4) · Mouth Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Otorhinolaryngologic Diseases (4) · Otorhinolaryngologic Neoplasms (4) · Pharyngeal Diseases (4) · Pharyngeal Neoplasms (4) · Stomatognathic Diseases (4) · Laryngeal Diseases (3) · Neoplasms, Squamous Cell (3) · Respiratory Tract Diseases (3)
130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Radiotherapy, Intensity-Modulated (1) · durvalumab (1) · ficlatuzumab (1) · pembrolizumab (1)
Klus Pharma Inc. (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Arizona (1) · Washington University School of Medicine (1)
United States (4)
Jared Weiss, MD (1) · Jordi Rodon Ahnert, MD, PhD (1) · Julie E. Bauman, MD, MPH (1) · Sana Karam, MD, PhD (1) · Sidharth Puram, MD, PhD (1)
P30CA023074 (1)